GleamWall
中文EN

HROW HARROW, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1360214 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY21.3%
TTM net income YoY-471.2%
TTM EPS YoY-484.6%
Revenue 3-yr CAGR38.5%
Net income 3-yr CAGR—

Margins

Gross margin73.5%
Operating margin-2.0%
Net margin-9.4%
FCF margin-6.7%
EBITDA margin-1.4%

Returns

ROE-74.8%
ROA-7.1%
ROIC (approx.)-3.5%
Asset turnover0.75x

Leverage & solvency

Liabilities / assets93.5%
Debt / equity0.00x
Current ratio2.29x
Interest coverage-0.26x

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-2.4%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$99.30M$70.66M$44.20M$89.09M$71.64M$63.74M$47.83M$66.83M
Cost of revenue$24.39M$20.30M$17.16M$18.47M$17.71M$16.23M$15.52M$14.13M
Gross profit$74.90M$50.36M$27.05M$70.62M$53.93M$47.51M$32.31M$52.70M
R&D expense$10.29M$8.07M$5.89M$11.72M$3.32M$2.87M$3.03M$4.75M
SG&A expense$53.15M$53.30M$43.23M$43.31M$35.86M$33.23M$40.51M$34.79M
Operating income$11.47M-$11.01M-$22.08M$15.59M$14.75M$11.41M-$11.23M$12.90M
Interest expense$6.21M$6.26M$5.50M$5.19M$6.04M$6.41M$6.55M$6.38M
Pretax income$10.26M-$17.27M-$27.58M$10.40M$1.02M$5.00M-$17.78M$6.26M
Income tax$506,000$0$25,000$3.77M$0$0—-$514,000
Net income$9.76M-$17.27M-$27.60M$6.63M$1.02M$5.00M-$17.78M$6.78M
EBITDA$11.92M-$10.55M-$21.62M$16.05M$15.07M$11.76M-$10.77M$13.37M
EPS (basic)0.26-0.46-0.74—0.030.14-0.50—
EPS (diluted)0.25-0.46-0.74—0.030.13-0.50—
Weighted avg. shares (diluted)38.53M37.35M37.23M—38.88M38.85M35.83M—
Balance sheet
Cash & equivalents$75.34M$83.89M$94.64M$72.93M$74.29M$52.96M$66.73M$47.25M
Receivables$155.31M$118.56M$101.26M$110.89M$77.60M$78.82M$77.06M$116.37M
Inventory$19.22M$16.91M$16.50M$13.52M$12.83M$11.55M$10.72M$10.70M
Current assets$261.33M$229.31M$226.38M$211.75M$177.60M$154.89M$169.53M$189.65M
PP&E, net$2.82M$2.96M$3.13M$3.26M$3.38M$3.51M$3.57M$3.73M
Goodwill$332,000$332,000$332,000$332,000$332,000$332,000$332,000$332,000
Intangibles$170.03M$175.57M$181.05M$175.17M$172.46M$176.67M$180.76M$184.95M
Total assets$443.02M$416.82M$419.54M$399.48M$363.07M$345.03M$364.16M$388.97M
Current liabilities$114.22M$102.17M$91.44M$96.30M$65.40M$248.88M$186.99M$91.34M
Long-term debt——$300.00M$250.00M$347.24M$250.62M$256.91M$262.74M
Total debt——$300.00M$250.00M$347.24M$250.62M$256.91M$262.74M
Total liabilities$414.19M$401.97M$391.19M$347.39M$316.41M$295.73M$308.07M$319.67M
Shareholders' equity$29.19M$15.20M$28.71M$52.45M$47.02M$49.65M$56.45M$69.65M
Net debt——$205.36M$177.07M$272.95M$197.66M$190.19M$215.49M
Shares outstanding37.52M37.48M37.27M37.23M37.03M36.71M35.65M35.62M
Cash flow statement
Operating cash flow-$8.62M-$9.76M-$8.99M$8.41M$16.59M-$803,000$19.67M-$17.78M
Capital expenditure$375,000$491,000$194,000$341,000$210,000$166,000$170,000$555,000
Free cash flow-$8.99M-$10.25M-$9.19M$8.07M$16.38M-$969,000$19.50M-$18.33M
Investing cash flow-$406,000-$534,000-$18.20M-$4.73M-$225,000-$293,000-$212,000-$37.56M
Financing cash flow$469,000-$466,000$48.91M-$5.04M$4.96M-$12.67M$23,000$29.98M
Depreciation & amortization$446,000$460,000$455,000$464,000$326,000$347,000$465,000$468,000
Stock-based compensation$3.73M$3.79M$3.84M$3.80M$3.27M$875,000$4.56M$4.79M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.